The World Health Organization (WHO) has issued a serious global warning about several contaminated Indian cough syrups after reports linked them to the deaths of children in central India. These medicines were found to contain a toxic industrial chemical far beyond safe limits, prompting a global safety alert for health authorities, doctors, and families. The WHO’s announcement highlights risks to children’s health and calls for urgent actions to remove these products from circulation and prevent further tragedies.
What Happened?
In October 2025, authorities in India’s Madhya Pradesh state reported that dozens of young children died after consuming cough syrup products for routine cold and cough symptoms. Laboratory tests uncovered that the medicines contained diethylene glycol (DEG), a highly toxic chemical used in industrial solvents, in quantities far exceeding safety standards — levels nearly 500 times above acceptable limits.
The WHO was notified by the Central Drugs Standard Control Organization (CDSCO), India’s national drug regulatory authority, after clusters of severe illness and fatalities were observed among children who had recently taken the syrups.
Which Cough Syrups Are Affected?
The WHO Medical Product Alert identified three substandard cough syrups made in India:
- Coldrif – manufactured by Sresan Pharmaceutical
- Respifresh TR – manufactured by Rednex Pharmaceuticals
- ReLife – manufactured by Shape Pharma
All three products were found to be contaminated and unsafe for consumption, especially for children. Health authorities have ordered production halts and initiated recalls of these medicines.
Why Is This Dangerous?
Diethylene Glycol (DEG) is not a medicinal ingredient. It is an industrial solvent used in antifreeze and brake fluids and is toxic when ingested, especially by young children. Even small amounts can cause acute kidney injury, neurological symptoms, and death.
The contaminated syrups, when consumed, can lead to:
- vomiting and abdominal pain
- diarrhea and dehydration
- inability to pass urine
- kidney failure and death
This severe toxicity makes these syrups extremely unsafe, especially for children under five years old.
Local and Global Response
India’s Actions
Indian regulators responded by:
- suspending production at the implicated manufacturing sites
- banning the sale of these cough syrups in several states
- recalling affected batches from pharmacies
- collaborating with WHO to track and monitor distribution
In some cases, manufacturing licenses were revoked for companies whose products tested positive for contaminants.
WHO’s Global Warning
The WHO has issued a worldwide alert, urging all national regulatory authorities to report immediately if they find these contaminated products in their borders and to increase market surveillance, especially in unregulated supply channels. Healthcare professionals are also advised to watch for adverse reactions and notify health authorities if they encounter these medicines.
The alert also stresses that no evidence currently shows these contaminated syrups have been exported from India, but vigilance is recommended in all markets.
Broader Implications
This tragedy has once again sparked discussions about the gaps in regulatory oversight, quality testing, and pharmaceutical supply chain safety — not only in India but globally. Previous outbreaks linked to degraded medicines have occurred in other countries, underscoring the critical need for stronger quality controls in medicine manufacturing.
Frequently Asked Questions (FAQs)
What caused the cough syrup contamination?
The syrups were contaminated with diethylene glycol (DEG), a toxic industrial chemical not intended for medicinal use. DEG can cause kidney failure and other life-threatening symptoms when ingested.
Which products are included in the WHO alert?
The WHO alert covers specific batches of Coldrif, Respifresh TR, and ReLife cough syrups manufactured in India that failed safety standards.
Have these contaminated syrups been exported?
According to Indian regulators, there is no evidence that the contaminated syrups were exported to other countries. However, WHO urges global monitoring to be sure.
What should parents do if they have these syrups?
If you have any of the identified products, do not use them and contact health authorities or your national drug regulator for guidance immediately.
How can similar incidents be prevented in the future?
Strengthening pharmaceutical quality testing, improving supply chain monitoring, and enforcing stricter regulatory oversight are key steps to preventing contaminated medicines from reaching patients.
Conclusion
The World Health Organization’s warning over contaminated Indian cough syrups is a stark reminder of the dangers posed by substandard medicines, particularly to children. The deaths linked to these toxic products underscore the importance of rigorous quality testing, strong regulatory systems, and international cooperation to ensure the safety of all medicines in the global market. Health authorities, caregivers, and families must remain alert and report any suspected substandard medicines to prevent further loss of life.
